-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

Benzinga·10/09/2026 16:06:43
Listen to the news
Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.